Table S1 and S2 from Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer
Table S1 and S2. Suplementary Table 1. Adverse events during chemoradiation with panitumumab, according to CTCAE criteria (after 43 days). Suplementary Table 2. Tumor-size and radiation fields between cohorts.